Home
As a proud partner of the Canadian hospital system, In-Common Laboratories (ICL) is celebrating Canadian innovation and successes in medical laboratory testing. Below, read just a few of the many Canadian tests our public system partners are proud to offer.
A made-in-Canada breakthrough in clinical chemistry: There are more than 100 peer-reviewed publications agreeing on Phospho-Tau 217 (pTau217) plasma as a recommended, highly specific biomarker of Alzheimer’s Disease. Learn more about how to order this test through ICL and our partners at BC Neuroimmunology »
Glutamic Acid Decarboxylase (GAD65) is a well-known biomarker for assessing susceptibility to autoimmune (type 1) diabetes and helping distinguish between patients with type 1 and type 2 diabetes. We offer this testing through our partners at London Health Sciences Centre:
Canadian urine drug screen testing is readily available to order. The panel is continually evolving to include testing for emerging psychoactive compounds from the unregulated drug market, as identified by Ontario’s Drug Checking Services. Learn more about how to offer this broad spectrum screening panel through ICL and our partners at Unity Health Toronto.
NfL is a new blood-based biomarker for Multiple Sclerosis, improving prediction of disease severity and progression. This test is also valuable for clinicians assessing a patient’s response to therapy. We offer this testing through various Canadian testing partners:
Do you have a Canadian lab test worth bragging about? Let us know!